About Proxygen

Proxygen is a biotechnology company developing molecular glue degraders that target and degrade disease-causing proteins through the cell's natural protein recycling machinery. This approach aims to provide new therapeutic options for cancer and other life-threatening diseases by effectively eliminating harmful proteins rather than merely inhibiting their function.

```xml <problem> Many diseases are caused by specific proteins within cells. Traditional drugs often only inhibit these proteins, rather than eliminating them entirely, which can limit their effectiveness and lead to drug resistance. Developing therapies that can selectively remove these disease-causing proteins remains a significant challenge. </problem> <solution> Proxygen is developing a novel class of therapeutics called molecular glue degraders. These small molecules work by binding to both a target protein and an E3 ubiquitin ligase, effectively bringing them into close proximity. This induced proximity triggers the cell's natural protein degradation machinery to tag the target protein for destruction. By leveraging this mechanism, Proxygen's approach aims to completely eliminate disease-causing proteins, offering a potentially more effective and durable therapeutic strategy compared to traditional inhibitors. </solution> <features> - Focus on molecular glue degraders, a novel drug modality with the potential to target any protein in the cell. - Catalytic mechanism of action, where a single glue degrader molecule can degrade multiple target protein molecules. - Highly selective targeting of specific disease-causing proteins. - Potential for overcoming drug resistance by eliminating the target protein rather than just inhibiting its function. </features> <target_audience> The primary target audience includes patients suffering from cancers and other life-threatening diseases where specific proteins play a critical role in disease progression. </target_audience> ```

What does Proxygen do?

Where is Proxygen located?

Proxygen is based in Vienna, Austria.

Location

Vienna, Austria

Employees

42 employees

Major Investors

Boehringer Ingelheim

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Proxygen

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

proxygen.com 3K+

Crunchbase

Vienna, Austria

Funding

Major Investors

Boehringer Ingelheim

Team (40+)

No team information available.

Company Description

Problem

Many diseases are caused by specific proteins within cells. Traditional drugs often only inhibit these proteins, rather than eliminating them entirely, which can limit their effectiveness and lead to drug resistance. Developing therapies that can selectively remove these disease-causing proteins remains a significant challenge.

Solution

Proxygen is developing a novel class of therapeutics called molecular glue degraders. These small molecules work by binding to both a target protein and an E3 ubiquitin ligase, effectively bringing them into close proximity. This induced proximity triggers the cell's natural protein degradation machinery to tag the target protein for destruction. By leveraging this mechanism, Proxygen's approach aims to completely eliminate disease-causing proteins, offering a potentially more effective and durable therapeutic strategy compared to traditional inhibitors.

Features

Focus on molecular glue degraders, a novel drug modality with the potential to target any protein in the cell.

Catalytic mechanism of action, where a single glue degrader molecule can degrade multiple target protein molecules.

Highly selective targeting of specific disease-causing proteins.

Potential for overcoming drug resistance by eliminating the target protein rather than just inhibiting its function.

Target Audience

The primary target audience includes patients suffering from cancers and other life-threatening diseases where specific proteins play a critical role in disease progression.